Background: There are few data on the use of ceftriaxone in pregnant women diagnosed with syphilis. The aim of this study was to investigate the safety and efficacy of ceftriaxone as an alternative treatment option for syphilis during pregnancy. Methods: A retrospective analysis of 79 pregnant women diagnosed with syphilis and treated with ceftriaxone was conducted. Results: No cases of intolerance, Jarisch-Herxheimer reactions, or allergic reactions were recorded. The average time to seronegativation for secondary syphilis with symptoms was 6.14 months ± 2.76, and for latent forms, it was 7.52 months ± 1.84. Patients received no additional treatment. No serious adverse drug reactions were reported. Conclusions: Data from our study support the use of ceftriaxone as an effective and safe alternative treatment for pregnant women diagnosed with syphilis when penicillin therapy is contraindicated or unavailable.
Background and Objectives: Atopic dermatitis and psoriasis are life-long inflammatory diseases affecting more than just the skin. Although their link with mental comorbidities has been established, the role of using self-assessment questionnaires is still debated. The aim of our study was to evaluate differences in the quality of life (DLQI) as well as depression (PHQ-9) and anxiety (GAD-7) questionnaire data and determine their link with individual patient and skin disease factors. Materials and Methods: Demographic, clinical and questionnaire data were collected from Riga 1st hospitals archive. For statistical evaluation, the Mann–Whitney U test and Spearman’s rank correlation coefficient were used. Results: The median DLQI for atopic dermatitis and psoriasis was 10.5 and 10, respectively. The prevalence among women with atopic dermatitis who had a PHQ-9 ≥ 10 was 42.9%, compared to 50.0% in men, and GAD-7 ≥ 10 prevalence was 14.3% and 20.0%, respectively. Psoriatic women had a PHQ-9 ≥ 10 prevalence of 25.0% compared with 28.9% in men. The prevalence of GAD-7 ≥ 10 was 20.0% in females and 15.8% in males. GAD-7 score was elevated in patients with psoriatic genital involvement. Multiple positive correlations were noted between PHQ-9, GAD-7 and DLQI scores. Conclusions: Patient quality of life and prevalence of anxiety and depression symptoms are impacted by psoriasis and atopic dermatitis, with similar patterns observed across genders and comorbidities. Genital involvement could be associated with more severe anxiety symptoms. The correlations between PHQ-9, GAD-7 and DLQI scores indicate that further evaluation might be necessary if quality of life is impaired.
Background and Objectives: Psoriasis patients aged over 65 years, especially those with chronic comorbidities, constitute an increasingly important patient population. In this group, the selection of therapy, along with its efficacy and safety, is of relevance. Materials and Methods: A single-center retrospective analysis of clinical records of patients aged ≥ 65 years with moderate to severe plaque psoriasis, treated with biologic therapies. The study covered the period 2019–2025. Results: A total of 38 patients were included. Biologic switching occurred in 15 patients (39.5%). The primary reason for switching was loss of efficacy (86.7%), while adverse events accounted for 13.3% of cases. The mean duration from initiation of adalimumab (the mandatory first-line biologic therapy) to switching was 325 ± 191 days. Baseline PASI did not differ significantly between groups (p = 0.139). Psoriatic arthritis was significantly less frequent among patients who switched therapy (13.3% vs. 56.5%, p = 0.008). No significant associations were observed between switching and comorbidities or overall comorbidity burden (p > 0.05). Clinically relevant adverse events included infections, cardiovascular events, malignancies, and autoimmune laboratory abnormalities. Conclusions: Biologic therapy in elderly psoriasis patients appears to be generally well tolerated, based on descriptive real-world data. Treatment switching was primarily driven by loss of efficacy rather than comorbidities.
15 September 2026 in SN Comprehensive Clinical Medicine
Background/Objectives: Psoriasis is a systemic immune-mediated inflammatory disease associated with endothelial dysfunction and cardiovascular risk. This study evaluated relationships among clinical severity, cytokine activity, systemic vascular resistance, and skin microvascular reactivity in chronic plaque psoriasis before and after therapy. Methods: In this prospective longitudinal study, 34 patients with chronic plaque psoriasis and 19 matched controls were assessed. Patients were examined at baseline and after 12 months of clinically indicated systemic therapy. Psoriasis Area and Severity Index (PASI), serum IL-17A, IL-22, TNF-α, IL-12(p40), IL-10, VEGF-A, total peripheral resistance, and laser Doppler flowmetry post-occlusive reactive hyperemia indices were analysed. Results: PASI decreased markedly after therapy, from 20.6 ± 7.7 to 4.1 ± 5.3, with excellent discrimination between pre- and post-treatment states. IL-17A, IL-22, and IL-12(p40) decreased significantly, while TNF-α remained associated with disease severity. Total peripheral resistance and delayed psoriatic-skin hyperemia persisted and correlated with inflammatory/angiogenic markers, particularly IL-12(p40) and VEGF-A. Conclusions: Long-term therapy improves clinical and cytokine profiles in psoriasis, but vascular dysfunction may persist despite cutaneous improvement. Integrated cytokine–vascular assessment may complement PASI for evaluating systemic inflammatory burden and cardiovascular risk.
Background and Objectives: Psoriasis vulgaris features epidermal barrier dysfunction. Materials and Methods: Barrier function changes were prospectively evaluated over 12 weeks during TNF-α inhibition with adalimumab, along with concurrent changes in disease severity and quality of life. Adults with moderate-to-severe plaque psoriasis initiating adalimumab (80 mg loading on day 1; 40 mg every other week thereafter, starting day 8) underwent assessments at baseline and at week 12 (n = 9; mean age 44.1 ± 14.9 years, range 20–61). Transepidermal water loss (TEWL; g/m2/h) and skin pH were measured at the elbow, lower leg, abdomen, back, and scalp; PASI, BSA, and DLQI were recorded. The measurements were standardized, though room temperature/humidity were not identical between visits. Results: The clinical indices improved markedly and TEWL also decreased at all sites—the elbow, lower leg, abdomen, back, and scalp—indicating barrier recovery; in contrast, the pH remained within a mildly acidic range at all sites. Lesion-to-non-lesion conversion occurred, and no site worsened. Conclusions: In summary, 12 weeks of adalimumab were associated with a notable clinical improvement and consistent, site-spanning reductions in TEWL, whereas skin surface pH showed no material change. TEWL appears to be a sensitive objective adjunct to clinical indices for monitoring response.